Clinical Trial

Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer

Study acronym: ASpiRE
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
ASpiRE will investigate the effect of the drug SX-682 in combination with Apalutamide in men suffering from metastatic castration-resistant prostate cancer (mCRPC).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-05-23; most recent amendment 2026-04-14.
Trial Details
NCT Number NCT07002320
Lead Sponsor Institute of Cancer Research, United Kingdom
Collaborators: Prostate Cancer UK, Janssen Pharmaceutica N.V., Belgium, Oncology Institute of Southern Switzerland, Syntrix Biosystems, Inc., Royal Marsden NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, Belfast Health and Social Care Trust, Institute of Oncology Research (IOR)
Conditions Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Enrollment 78 participants
Start Date 2025-04-28
Primary Completion 2029-10 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-15